使用医用大麻和娱乐性大麻的非癌症疼痛和长期使用处方阿片类药物患者的特征。

IF 4.1 Q1 PHARMACOLOGY & PHARMACY
Whitney M Davidson, Anika Mahavni, Timothy Chrusciel, Joanne Salas, Lisa R Miller-Matero, Mark D Sullivan, Celeste Zabel, Patrick J Lustman, Brian K Ahmedani, Jeffrey F Scherrer
{"title":"使用医用大麻和娱乐性大麻的非癌症疼痛和长期使用处方阿片类药物患者的特征。","authors":"Whitney M Davidson, Anika Mahavni, Timothy Chrusciel, Joanne Salas, Lisa R Miller-Matero, Mark D Sullivan, Celeste Zabel, Patrick J Lustman, Brian K Ahmedani, Jeffrey F Scherrer","doi":"10.1186/s42238-024-00218-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Marijuana use is increasingly common among patients with chronic non-cancer pain (CNCP) and long-term opioid therapy (LTOT). We determined if lifetime recreational and medical marijuana use were associated with more frequent and higher dose prescription opioid use.</p><p><strong>Design: </strong>Cross-sectional SUBJECTS: Eligible patients (n=1,037), who had a new period of prescription opioid use lasting 30-90 days, were recruited from two midwestern health care systems to a study of long-term prescription opioid use and mental health outcomes. The present cross-sectional analyses uses baseline data from this on-going cohort study.</p><p><strong>Methods: </strong>Primary exposures were participant reported lifetime recreational and medical marijuana use versus no lifetime marijuana use. Prescription opioid characteristics included daily versus non-daily opioid use and ≥50 morphine milligram equivalent (MME) dose per day vs. <50 MME. Multivariate, logistic regression models estimated the association between lifetime recreational and medical marijuana use vs. no use and odds of daily and higher dose prescription opioid use, before and after adjusting for confounding.</p><p><strong>Results: </strong>The sample was an average of 54.9 (SD±11.3) years of age, 57.3% identified as female gender, 75.2% identified as White, and 22.5% identified as Black race. Among all participants, 44.4% were never marijuana users, 21.3% were recreational only, 7.7% medical only and 26.6% were both recreational and medical marijuana users. After controlling for all confounders, lifetime recreational marijuana use, as compared to no use, was significantly associated with increased odds of daily prescription opioid use (OR=1.61; 95%CI:1.02-2.54). There was no association between lifetime recreational or medical marijuana use and daily opioid dose.</p><p><strong>Conclusion: </strong>Lifetime medical marijuana use is not linked to current opioid dose, but lifetime recreational use is associated with more than a 60% odds of being a daily prescription opioid user. Screening for lifetime recreational marijuana use may identify patients with chronic pain who are vulnerable to daily opioid use which increases risk for adverse opioid outcomes. Prospective data is needed to determine how marijuana use influences the course of LTOT and vice versa.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882913/pdf/","citationCount":"0","resultStr":"{\"title\":\"Characteristics of patients with non-cancer pain and long-term prescription opioid use who have used medical versus recreational marijuana.\",\"authors\":\"Whitney M Davidson, Anika Mahavni, Timothy Chrusciel, Joanne Salas, Lisa R Miller-Matero, Mark D Sullivan, Celeste Zabel, Patrick J Lustman, Brian K Ahmedani, Jeffrey F Scherrer\",\"doi\":\"10.1186/s42238-024-00218-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Marijuana use is increasingly common among patients with chronic non-cancer pain (CNCP) and long-term opioid therapy (LTOT). We determined if lifetime recreational and medical marijuana use were associated with more frequent and higher dose prescription opioid use.</p><p><strong>Design: </strong>Cross-sectional SUBJECTS: Eligible patients (n=1,037), who had a new period of prescription opioid use lasting 30-90 days, were recruited from two midwestern health care systems to a study of long-term prescription opioid use and mental health outcomes. The present cross-sectional analyses uses baseline data from this on-going cohort study.</p><p><strong>Methods: </strong>Primary exposures were participant reported lifetime recreational and medical marijuana use versus no lifetime marijuana use. Prescription opioid characteristics included daily versus non-daily opioid use and ≥50 morphine milligram equivalent (MME) dose per day vs. <50 MME. Multivariate, logistic regression models estimated the association between lifetime recreational and medical marijuana use vs. no use and odds of daily and higher dose prescription opioid use, before and after adjusting for confounding.</p><p><strong>Results: </strong>The sample was an average of 54.9 (SD±11.3) years of age, 57.3% identified as female gender, 75.2% identified as White, and 22.5% identified as Black race. Among all participants, 44.4% were never marijuana users, 21.3% were recreational only, 7.7% medical only and 26.6% were both recreational and medical marijuana users. After controlling for all confounders, lifetime recreational marijuana use, as compared to no use, was significantly associated with increased odds of daily prescription opioid use (OR=1.61; 95%CI:1.02-2.54). There was no association between lifetime recreational or medical marijuana use and daily opioid dose.</p><p><strong>Conclusion: </strong>Lifetime medical marijuana use is not linked to current opioid dose, but lifetime recreational use is associated with more than a 60% odds of being a daily prescription opioid user. Screening for lifetime recreational marijuana use may identify patients with chronic pain who are vulnerable to daily opioid use which increases risk for adverse opioid outcomes. Prospective data is needed to determine how marijuana use influences the course of LTOT and vice versa.</p>\",\"PeriodicalId\":101310,\"journal\":{\"name\":\"Journal of cannabis research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2024-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10882913/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cannabis research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s42238-024-00218-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cannabis research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-024-00218-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:吸食大麻在慢性非癌性疼痛(CNCP)和长期阿片类药物治疗(LTOT)患者中越来越常见。我们研究了终生吸食娱乐性和医用大麻是否与更频繁、更大剂量地使用处方阿片类药物有关:设计:横断面受试者:从两个中西部医疗保健系统招募了符合条件的患者(n=1,037),这些患者新近使用处方阿片类药物的时间持续了 30-90 天,参加了一项关于长期使用处方阿片类药物和心理健康结果的研究。本横断面分析使用了这项正在进行的队列研究的基线数据:主要暴露因素是参与者报告的终生使用娱乐性和医用大麻与终生不使用大麻的情况。处方阿片类药物的特征包括每日与非每日使用阿片类药物,以及每日吗啡毫克当量(MME)剂量≥50 与≥50:样本平均年龄为 54.9 岁(SD±11.3),57.3% 为女性,75.2% 为白人,22.5% 为黑人。在所有参与者中,44.4%的人从未吸食过大麻,21.3%的人只吸食娱乐性大麻,7.7%的人只吸食医用大麻,26.6%的人既吸食娱乐性大麻也吸食医用大麻。在控制了所有混杂因素后,与不使用大麻相比,终生娱乐性使用大麻与每天使用处方阿片类药物的几率增加显著相关(OR=1.61;95%CI:1.02-2.54)。终生使用娱乐性或医用大麻与每日阿片类药物剂量之间没有关联:结论:终生使用医用大麻与当前阿片类药物剂量无关,但终生使用娱乐性大麻与超过 60% 的每日处方阿片类药物使用者相关。对终生吸食娱乐性大麻的患者进行筛查,可能会发现容易每日使用阿片类药物的慢性疼痛患者,这将增加阿片类药物不良后果的风险。需要前瞻性数据来确定吸食大麻如何影响 LTOT 病程,反之亦然。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Characteristics of patients with non-cancer pain and long-term prescription opioid use who have used medical versus recreational marijuana.

Objective: Marijuana use is increasingly common among patients with chronic non-cancer pain (CNCP) and long-term opioid therapy (LTOT). We determined if lifetime recreational and medical marijuana use were associated with more frequent and higher dose prescription opioid use.

Design: Cross-sectional SUBJECTS: Eligible patients (n=1,037), who had a new period of prescription opioid use lasting 30-90 days, were recruited from two midwestern health care systems to a study of long-term prescription opioid use and mental health outcomes. The present cross-sectional analyses uses baseline data from this on-going cohort study.

Methods: Primary exposures were participant reported lifetime recreational and medical marijuana use versus no lifetime marijuana use. Prescription opioid characteristics included daily versus non-daily opioid use and ≥50 morphine milligram equivalent (MME) dose per day vs. <50 MME. Multivariate, logistic regression models estimated the association between lifetime recreational and medical marijuana use vs. no use and odds of daily and higher dose prescription opioid use, before and after adjusting for confounding.

Results: The sample was an average of 54.9 (SD±11.3) years of age, 57.3% identified as female gender, 75.2% identified as White, and 22.5% identified as Black race. Among all participants, 44.4% were never marijuana users, 21.3% were recreational only, 7.7% medical only and 26.6% were both recreational and medical marijuana users. After controlling for all confounders, lifetime recreational marijuana use, as compared to no use, was significantly associated with increased odds of daily prescription opioid use (OR=1.61; 95%CI:1.02-2.54). There was no association between lifetime recreational or medical marijuana use and daily opioid dose.

Conclusion: Lifetime medical marijuana use is not linked to current opioid dose, but lifetime recreational use is associated with more than a 60% odds of being a daily prescription opioid user. Screening for lifetime recreational marijuana use may identify patients with chronic pain who are vulnerable to daily opioid use which increases risk for adverse opioid outcomes. Prospective data is needed to determine how marijuana use influences the course of LTOT and vice versa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信